This is a phase I study to evaluate the safety of ALLO-ASC-CD for the treatment of crohn'
disease. ALLO-ASC-CD is intravenous infusion containing allogenic adipose-derived mesenchymal
Adipose-derived stem cells are directed to injured tissue, and reduce inflammation.
Furthermore, their immunomodulatory effects are significant for treating immune-related
diseases, such as crohn's disease. Finally, ALLO-ASC-CD may provide a new option in treating
a crohn's disease.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.